about
Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides.Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.Insulin resistance.Nature's own pharmacy: the diabetes perspective.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Drugs on the horizon for treatment of type 2 diabetes.
@en
type
label
Drugs on the horizon for treatment of type 2 diabetes.
@en
prefLabel
Drugs on the horizon for treatment of type 2 diabetes.
@en
P2860
P1433
P1476
Drugs on the horizon for treatment of type 2 diabetes.
@en
P2093
P2860
P304
P356
10.1111/J.1464-5491.1995.TB00526.X
P577
1995-06-01T00:00:00Z